Results 41 to 50 of about 413,339 (385)

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation

BMC Cancer, 2008
Background Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells.
Zhou Chun-lei, Xu Qiong, Liang Yu, Jia Jing, Lu Rong, Chen Li-juan, Zhu Zhi-feng, Wang Li, Wang Song, Yao Zhi   +9 more
doaj   +1 more source

Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. [PDF]

PLoS ONE, 2015
Doxorubicin has been shown to inhibit proliferation of cancer cells through proteolytic activation of CREB3L1 (cAMP response element binding protein 3-like 1), a transcription factor synthesized as a membrane-bound precursor.
Bray Denard, Andrea Pavia-Jimenez, Weina Chen, Noelle S Williams, Harris Naina, Robert Collins, James Brugarolas, Jin Ye   +7 more
doaj   +1 more source

Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer [PDF]

, 2015
Kinase suppressor of Ras 1 (KSR1) has been implicated in tumorigenesis in multiple cancers, including skin, pancreatic and lung carcinomas. However, our recent study revealed a role of KSR1 as a tumour suppressor in breast cancer, the expression of which
A Franceschini, AA Adjei, Arnhild Grothey, B Gyorffy, Cancer Genome Atlas Network, F Yan, F Yan, Georgios Giamas, H Xing, H Zhang, H Zhang, H Zhang, HR Xing, Hua Zhang, I Youlyouz-Marfak, J Cox, J Cox, J Lozano, J Stebbing, J Wielemaker, J Xu, J Zhang, Joao Nunes, Justin Stebbing, JV Olsen, K Kornfeld, L Hannesdottir, M Alcoceba, M Ashburner, M Kim, M Sundaram, M Therrien, M Therrien, Nicos Angelopoulos, NR Michaud, O Tacar, P Tymoszuk, PJ Klutho, R Kaneno, S Datta, S Falcon, S Zhu, Y Cao, Y Pommier, Y Xu, Y Zhang, Y Zhang, Yichen Xu, YJ Jeon   +48 more
core   +3 more sources

Platelet-rich plasma inhibits Adriamycin-induced inflammation via blocking the NF-κB pathway in articular chondrocytes

Molecular Medicine, 2021
Background Previous studies showed that doxorubicin could lead to osteoarthritis (OA) by inducing chondrocyte inflammation and apoptosis. Besides, it is reported that platelet-rich plasma (PRP) could suppress the activation of inflammatory NF-κB ...
Haijun Zhao, Weijie Zhu, Wude Mao, Chengkai Shen   +3 more
doaj   +1 more source

Sulbactam-enhanced cytotoxicity of doxorubicin in breast cancer cells

Cancer Cell International, 2018
Background Multidrug resistance (MDR) is a major obstacle in breast cancer treatment. The predominant mechanism underlying MDR is an increase in the activity of adenosine triphosphate (ATP)-dependent drug efflux transporters.
Shao-hsuan Wen, Shey-chiang Su, Bo-huang Liou, Cheng-hao Lin, Kuan-rong Lee   +4 more
doaj   +1 more source

Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells [PDF]

, 2009
BACKGROUND: Chemoresistance acquisition may influence cancer cell biology. Here, bioinformatics analysis of gene expression data was used to identify chemoresistance-associated changes in neuroblastoma biology.
Barth, Susanne, Breitling, Rainer, Cinatl jr., Jindrich, Cinatl, Jaroslav, Cinatl, Jindrich, Doerr, Hans W., Hinsch, Nora, Klassert, Denise, Mayer, Bernd, Michaelis, Martin, Suhan, Tatyana   +10 more
core   +6 more sources

Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application

Pharmaceutics, 2023
Doxorubicin is a potent chemotherapeutic drug; however, its clinical application has been limited due to its cardiotoxicity. One of the major mechanisms of doxorubicin-induced cardiotoxicity is the induction of oxidative stress.
Tanawat Attachaipanich, Siriporn C. Chattipakorn, Nipon Chattipakorn   +2 more
doaj   +1 more source

The Tumor-Suppressive Human Circular RNA CircITCH Sponges miR-330-5p to Ameliorate Doxorubicin-Induced Cardiotoxicity Through Upregulating SIRT6, Survivin, and SERCA2a

Circulation Research, 2020
Supplemental Digital Content is available in the text. Rationale: Doxorubicin is one of the most potent antitumor agents available; however, its clinical use is restricted because it poses a risk of severe cardiotoxicity.
Dong Han, Yongjun Wang, Yabin Wang, Xinchun Dai, Tingwen Zhou, Jiangwei Chen, B. Tao, Jibin Zhang, F. Cao   +8 more
semanticscholar   +1 more source

Use of in vitro human keratinocyte models to study the effect of cooling on chemotherapy drug-induced cytotoxicity [PDF]

, 2014
A highly distressing side-effect of cancer chemotherapy is chemotherapy-induced alopecia (CIA). Scalp cooling remains the only treatment for CIA, yet there is no experimental evidence to support the cytoprotective capacity of cooling. We have established
Andrew Collett, Bodo, Boelsma, Boukamp, Breed, Brunsvig, Bulow, Christopher Dunnill, Corina J. van den Hurk, Dean, Deyrieux, Georgopoulos, Gregory, Grevelman, Inui, Itami, Itoh, Janssen, Janssen, Kayamba, Komen, Lane, Liu, Luanpitpong, Manon M. Komen, Margulis, Munstedt, Nabholtz, Nikolaos T. Georgopoulos, Omar Hussain, Paus, Protiere, Roh, van den Hurk, Wafaa Al-Tameemi, Wang, Watanabe   +36 more
core   +1 more source

TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC

Tumor Biology, 2017
The anticancer effect of doxorubicin is closely related to the generation of reactive oxygen species. On the contrary, doxorubicin-induced reactive oxygen species induces heart failure, a critical side effect of doxorubicin.
Yun Sun Lee, Young Joon Choi, JeeYun Lee, Da Mi Shim, Woong-Yang Park, Sung Wook Seo   +5 more
doaj   +1 more source